|
Model 1: Cycle number
|
|
Cycle number
|
1.44
|
1.12–1.85
|
0.004
|
|
Model 2: Cycle number plus chemotherapy type and factors
|
|
Cycle number
|
1.51
|
1.07–2.12
|
0.018
|
|
Chemotherapy type
| | |
0.254
|
|
Adjuvant vs Neoadjuvant
|
0.29
|
0.02–3.55
|
0.333
|
|
Palliative vs Neoadjuvant
|
0.77
|
0.05–10.95
|
0.844
|
|
Capecitabine
|
767 × 106
|
0 - Indefinite
|
1.000
|
|
Cyclophosphamide
|
1.80
|
0.46–7.01
|
0.400
|
|
Neuropathic pain treatment
|
1.18
|
0.08–18.03
|
0.904
|
|
Model 3: Biological measures
|
|
Hemoglobin
|
0.67
|
0.45–0.99
|
0.046
|
|
Leucocytes
|
1.00
|
1.00–1.00
|
0.189
|
|
Platelets
|
1.00
|
1.00–1.00
|
0.733
|
|
Model 4: Genes
|
|
ABCB1 rs1045642
|
0.92
|
0.40–2.12
|
0.848
|
|
CLOCK rs1801260 TT vs TC
|
0.29
|
0.07–1.15
|
0.077
|
|
COMT rs4680 (V/V & V/M vs M/M)
|
1.37
|
0.29–6.38
|
0.693
|
|
PER2 rs934945 (GG & GA) vs AA
|
0.56
|
0.02–13.02
|
0.716
|
|
CRY2 rs10838524 (GG & GA) vs AA
|
3.12
|
0.44–21.89
|
0.253
|
|
DRD2 rs6277 (CC & CT vs TT)
|
4.09
|
1.02–16.48
|
0.047
|
|
Model 5: Full factor modela
|
|
Cycle number
|
1.36
|
0.98–1.89
|
0.066
|
|
CLOCK rs1801260 TT vs TC
|
0.29
|
0.07–1.29
|
0.104
|
|
DRD2 rs6277 (CC & CT vs TT)
|
3.79
|
0.84–17.20
|
0.084
|
|
Hemoglobin
|
0.38
|
0.50–1.30
|
0.376
|
